Tests lymph node removal before chemoradiation for cervical cancer
Tests lymph node removal before chemoradiation in adults with stage IIICr cervical cancer.
Plain-language title generated from the registry record
Registry title: The Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103)
Key facts
- Where
- Chongqing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with stage IIICr cervical cancer and a large positive lymph node. It tests lymph node surgery before chemoradiation.
- Age
- 18 to 70 years
- Sex
- Women only
- Disease stage
- Cervical cancer stage IIICr confirmed by CT/MRI/PET/CT, with a positive lymph node whose short diameter is 15mm or more. Squamous cell, adenocarcinoma or adeno-squamous cell type.
- Earlier treatment
- No pelvic radiotherapy, pelvic artery embolization, partial or radical hysterectomy, or immunotherapy before.
Main reasons for not taking part
- Active or uncontrolled severe infection
- Active hepatitis B, liver cirrhosis or decompensated liver disease
- HIV positive or other immune deficiency
- Chronic kidney insufficiency or kidney failure
- Another cancer diagnosed within 5 years or needing treatment
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT04555226, who can take part
Where in China
- Chongqing Cancer HospitalChongqing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chongqing University Cancer Hospital
- Trial code
- NCT04555226
- Record updated
- 2 September 2025
- Original description
This is an national, prospective, multicenter and randomized clinical study designed to determine if patients with stage IIICr of cervical cancer have longer PFS and/or OS with lymph node dissection before CCRT when compared to CCRT.Read full original descriptionShow less
Randomized Controlled Trial of the Efficacy of Lymph Node Dissection on Stage IIICr of Cervical Cancer
This is an national, prospective, multicenter and randomized clinical study designed to determine if patients with stage IIICr of cervical cancer have longer PFS and/or OS with lymph node dissection before CCRT when compared to CCRT.
Inclusion: Histopathology: squamous cell carcinoma, adenocarcinoma, adeno-squamous cell carcinoma; Cervical cancer stage IIICr (confirmed by CT/MRI/PET/CT) and the short diameter of image-positive lymph node ≥15mm; ECOG score 0~1; Expected survival over 6 months; The serum or urine pregnancy test must be negative within 7 days before enrollment for the women of childbearing age who should agree that contraception must be used during the trial; No surgical contraindication.
Exclusion: Has had an allogenic tissue/solid organ transplant; Activity or uncontrol severe infection; Active hepatitis B, Liver cirrhosis, Decompensated liver disease; History of immune deficiency, including HIV positive or suffering from other immunodeficiency disease; Active autoimmune disease requiring systemic treatment (e.g., use of disease-modifying medications, corticosteroids, or immunosuppressive medications). Replacement therapies (e.g., thyroxine, insulin, or physiological corticosteroid replacement for adrenal or pituitary insufficiency) were not counted as systemic therapies, and subjects were permitted to use these therapies; Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis; Chronic renal insufficiency or renal failure; Has combined with other malignant tumor which diagnosed within 5 years and/or needed to be treated; Myocardial infarction, severe arrhythmia and NYHA (New York heart association)≥2 for congestive heart failure; A history of pelvic artery embolization; A history of pelvic radiotherapy; A history of partial hysterectomy or radical hysterectomy; A history of immunotherapy or undergoing immunotherapy; A history of severe allergic reactions to platinum-based chemotherapy drugs, pembrolizumab and/or any excipients; During the treatment for complications, the drugs which lead to serious liver and/or kidney function impairment need to be used, such as tuberculosis.